Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fosfomycin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources

[Improvement of the therapeutic efficacy of fosfomycin by addition of glucose-6-phosphate in the treatment of intraperitoneally infected mice (author's transl)].

The increase of antimicrobial activity of Fosfomycin by glucose-6-phosphate (G-6-P) has often been demonstrated by in vitro studies. However, this effect was never sufficiently established in vivo. Our study was carried out in order to investigate the effects of the addition of G-6-P to Fosfomycin in white mice (strain G.P. of N.I.H.), which were intraperitoneally infected with a strain of S. typhimurium (10(3) c.f.u/0.5 ml i.p.). One and six hours after the infection, 0.1 ml consisting of increasing doses of G-6-P (0, 5, 25, 50, 250 and 500 micrograms/g) and decreasing doses of Fosfomycin (15.6, 7.8, 3.9, 1.95, 0.98 and 0.49 micrograms/g) were applied i.m., using 10 animals for each combination. Tables 1 and 2 show the results of this therapy with regard to the reduction of the ED50 of Fosfomycin. It can be seen that the addition of 25 micrograms G-6-P/g body-weight significantly reduces the ED50 within the first days (Tab. 1), while doses of 50 and more micrograms G-6-P/g significantly reduce the ED50 during the whole investigation period (Tab. 2). These results justify the proposal to use a combination of Fosfomycin and G-6-P in clinical studies for the treatment of human infections.

Animals↗

[Pharmacokinetics of fosfomycin and otitis media].

The pharmacokinetics of fosfomycin in the ear and eye fluids and in serum are studied after intramuscular administration of 300 and 600 mg per kg respectively to 11 groups of 7 guniea pigs each. Maximal fosfomycin concentrations in the perilymph and aqueous humour are about 12% of the serum peak concentrations and the aqueous humour concentrations are similar to those of the aminoglycoside antibiotics, whereas the fosfomycin concentrations in the perilymph are twice as high as those in the aminoglycoside antibiotics. A retention of fosfomycin in the perilymph, similar to that of the aminoglycoside antibiotics, can be observed. The fosfomycin half-lives in serum, aqueous humour and perilymph are 1.1, 3,7 and 4.9 hours, respectively. The discussion mainly concerns the validity, after suitable adaptation, of the experimental results and their clinical importance for therapy and prophylaxis of the infectious inner ear complications due to the usual germs of chronic otitis media as well as for the treatment of certain eye infections.

Animals↗

Comparison of fosfomycin and teicoplanin in serum bactericidal activity against staphylococci.

A serum bactericidal test was established employing human sera of volunteers after intravenous administration of fosfomycin (CAS 23155-02-4) and teicoplanin (CAS 61036-62-2) against 40 staphylococcal strains (20 Staphylococcus aureus and 20 coagulase-negative staphylococci, 10 of each group being susceptible and 10 being resistant to oxacillin). Median serum inhibitory titres were highest for fosfomycin against oxacillin-susceptible Staphylococcus aureus. In the three other groups of strains, the activity of fosfomycin was comparable to that of teicoplanin. The killing curves showed over 99% killing within 24 h for both antibiotics. Here, fosfomycin exerted a rapid killing activity within 4-6 h and was more effective in bacterial growth reduction. It can be concluded that fosfomycin and teicoplanin exerted comparable serum bactericidal antibacterial activity against staphylococci.

Adult↗

Pharmacokinetics of fosfomycin in chickens after a single intravenous dose and tissue levels following chronic oral administration.

This paper describes the pharmacokinetics of fosfomycin following a single i.v. bolus dose (10 mg/kg of body weight) in broiler chickens. Serial blood samples were collected up to 5 h post-administration. Fosfomycin serum concentrations were determined by a microbiological method, using Proteus mirabilis as the test microorganism. The serum concentration versus time curves after i.v. administration followed a biexponential decline. The main pharmacokinetic variables were t1/2 lambda l = 23 min, t1/2 lambda n = 112 min, VDarea = 575 +/- 190 mL/kg and CLb = 3.12 +/- 0.44 mL.min-1.kg-1. Tissue levels of fosfomycin in kidney, liver, lung, muscle, heart, fat, gizzard and serum were also determined after oral chronic administration of the drug in drinking water (150 micrograms/mL). During the oral chronic administration period, high FOS concentrations in serum were maintained (mean 6.1 +/- 1.1 micrograms/mL), but a significant decline over time could be observed (P < 0.05). Fosfomycin was detected in all tissues except muscle, with mean concentrations ranging from 0.63 microgram/g in fat to 13.48 micrograms/g in kidney. Twenty-four hours after the treatment was finished, fosfomycin levels were below the assay detection limit in all tissues tested.

Adipose Tissue↗

Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from Pseudomonas aeruginosa.

The metalloglutathione transferase FosA catalyzes the conjugation of glutathione to carbon-1 of the antibiotic fosfomycin, rendering it ineffective as an antibacterial drug. Codon randomization and selection for the ability of resulting clones to confer fosfomycin resistance to Escherichia coli were used to identify residues critical for FosA function. Of the 24 codons chosen for randomization, 16 were found to be essential because only the wild type amino acid was selected. These included ligands to the Mn(2+) and the K(+), residues that furnish hydrogen bonds to fosfomycin, and residues located in a putative glutathione/fosfomycin-binding site. The remaining eight positions randomized were tolerant to substitutions. Site-directed mutagenesis of some of the essential and tolerant amino acids to alanine was performed, and the activity of the purified proteins was determined. Mutation of the residues that are within hydrogen bonding distance to the oxirane or phosphonate oxygens of fosfomycin resulted in variants with very low or no activity. Mutation of Ser(94), which bridges one of the phosphonate oxygens with a potassium ion, resulted in insoluble protein. The Y39A mutation in the putative glutathione-binding site resulted in a 4-fold increase in the apparent K(m) for glutathione. Only two of the amino acids in the substrate-binding site are conserved in the related fosfomycin resistance proteins FosB and FosX, whereas no amino acids in the putative glutathione-binding site are conserved.

Bacterial Proteins↗

Side effects of repeated ototopical application of fosfomycin. An animal study.

In view of the possible role of fosfomycin in the topical treatment of chronic suppurative otitis media, the effects of this drug on inner ear function were investigated. Fosfomycin (20% aqueous solution) was applied repeatedly to the round window membrane of both ears of pigmented guinea pigs. Hearing thresholds were determined by daily frequency-specific evoked response audiometry with stimulation frequencies ranging from 1 to 32 kHz. Both positive (neomycin) and negative (saline) controls were included. Results were analyzed statistically. No significant and progressive hearing loss was found with fosfomycin. At 32 kHz, however, the hearing levels at the end of the test period were significantly worse in the fosfomycin group than in the saline group.

Administration, Topical↗

Quantum mechanical calculations useful for determining the mechanism of action of fosfomycin.

CNDO/2 calculations were performed to determine at the molecular level the mechanism of action of the antibiotic fosfomycin, (--)-(1R,2S)-(1,2-epoxypropyl)phosphonic acid. Fosfomycin, a bacterial cell wall inhibitor, is known to act as a competitive inhibitor of N-acetylglucosamine-3-O-enolpyruvyl transferase, the normal substrate of which is phosphoenolpyruvate. Both compounds were studied, and the theoretical calculations revealed that the preferred conformations of phosphoenolpyruvate and fosfomycin presented the same spatial charge distributions on the active sites, the values of which are in complete agreement with the experimental observations. These results permit the projection of some details of the receptor, with implications for the modification of fosfomycin to increase its antibiotic activity.

Anti-Bacterial Agents↗

Fosfomycin trometamol: historical background and clinical development.

A brief historical review of the clinical development of fosfomycin is given. Fosfomycin has attracted great interest because of its broad spectrum of activity and excellent tolerability. However, some problems have arsen because of the rapid emergence of resistant strains, and the poor bioavailability by oral route. Fosfomycin trometamol (a salt of fosfomycin with tromethamine) overcomes this difficulty: in fact when given by oral route it reaches very high and persistent urinary concentrations (up to 48 h). This behaviour allows a long-lasting bactericidal activity in urine to be obtained and the emergence of resistant variants to be prevented. These characteristics allowed proposing the drug for the "single dose therapy" of lower uncomplicated urinary tract infections. The clinical trials confirmed that this assumption was correct, demonstrating the excellent therapeutic activity of the drug in this indication.

Administration, Oral↗

Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

The pharmacokinetics and in particular bioavailability of fosfomycin trometamol was studied and compared to the earlier emerging calcium salt formulation by administration of 50 mg/kg body weight orally of the two and an identical dose intravenously to all of eight healthy male volunteers. The serum and urine samples collected over 12 and 48 hours, respectively, were assayed microbiologically. The serum peak concentrations were 26.2 mg/l after trometamol and 6.5 mg/l after the calcium salt. Based on total area under the serum curves, the bioavailability of fosfomycin from the trometamol formulation was 42.3% compared to a mere 12% of the calcium salt. Urinary recovery was nearly completed within 12 hours, and the amounts eliminated in percentage of the doses were 87, 43, and 18% after the intravenous, the oral dose of trometamol and oral calcium salt, respectively. The serum half-life was 3.4 hours after intravenous administration, which demonstrates the inherent rate of elimination of fosfomycin. In comparison the half-life values were 3.6 hours after the trometamol dose, and 5.6 hours after the calcium salt. The longer elimination of the latter is explainable by the less complete absorption and consequent delayed absorption of fosfomycin from the calcium salt formulation. The antibacterial activity in urine upon administration of 50 mg/kg was prolonged to 48 hours in nearly all cases of trometamol orally and more than after the calcium salt orally or the sodium salt intravenously. A dose of 3 g for adults - or 50 mg/kg - is consistent with the findings in this study.

Administration, Oral↗

A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose.

In order to evaluate the efficacy and safety of fosfomycin trometamol as single dose oral treatment for acute cystitis in women, an open, multicenter comparative study was carried out in general practices in France, 386 women, aged 16 to 75 years, with clinical symptoms of acute cystitis were enrolled in the study to receive either a single 3 g oral dose of fosfomycin trometamol or a five-day course of 400 mg pipemidic acid twice daily. The diagnosis of cystitis was based on clinical symptoms and significant bacteriuria (greater than or equal to 10(5) cfu/ml midstream urine). Follow-up examinations were carried out five to ten and 28 days after the end of treatment, 289 and 244 patients, respectively, were available for clinical and bacteriological evaluation at short-term (five to ten days) and medium-term (28 days) post-treatment follow-up. Both regimens were comparable for clinical and bacteriological efficacy with short-term eradication rates of 122/146 in the fosfomycin trometamol group and 130/143 in the pipemidic acid group. The results of medium-term follow-up were 113/122 and 114/122 for the eradication rates of the respective groups. Both drugs were well tolerated. Side effects were mild and of significantly shorter duration in the fosfomycin trometamol group.

Administration, Oral↗

Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.

Two strains each of sensitive, penicillinase-producing, methicillin-resistant and "tolerant" Staphylococcus aureus were used to infect mice intramuscularly. The mice were then treated with three doses each of fosfomycin, vancomycin, rifampicin, fusidic acid, penicillin G, flucloxacillin or cefazolin intravenously. Infections due to sensitive strains were effectively treated with all antibiotics investigated except fusidic acid. Fosfomycin, vancomycin, rifampicin and flucloxacillin showed the best activity against penicillinase-producing strains. Fosfomycin and vancomycin were equally effective against infections due to methicillin-resistant S. aureus. Infections caused by "tolerant" strains again responded best to fosfomycin, vancomycin and rifampicin.

Animals↗

In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

The in vitro antibacterial activity of fosfomycin was compared to that of oxacillin, cefazolin, ceftriaxone and vancomycin against isolates of Staphylococcus aureus from patients treated at the University of Vienna General Hospital. Of 211 strains, 104 were methicillin-susceptible and 107 were methicillin-resistant. Fosfomycin inhibited over 90% of the strains at concentrations of less than or equal to 64 mg/l, independent of methicillin susceptibility or resistance. The minimal bactericidal concentrations (MBC) were one dilution above the minimal inhibitory concentrations (MIC). Vancomycin showed activity similar to fosfomycin while other beta-lactam antibiotics such as oxacillin, cefazolin and ceftriaxone were inactive against methicillin-resistant S. aureus. Fosfomycin at a high dosage seems to be a potential drug for the treatment of infections due to methicillin-resistant S. aureus.

Anti-Bacterial Agents↗

In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate.

Determination of the minimal inhibitory concentration of fosfomycin in the agar dilution test on Mueller-Hinton agar showed that the addition of glucose-6-phosphate to the nutrient medium potentiates the action of fosfomycin against Escherichia coli, Klebsiella, Enterobacter, Citrobacter and Staphylococcus aureus, sometimes by as much as 256-fold. Such a potentiation of action was not detectable with Serratia marcescens, the individual Proteus species, Pseudomonas aeruginosa or enterococci. Fosfomycin is very effective against most medically important bacterial species on Mueller-Hinton agar containing 25 micrograms/ml glucose-6-phosphate. Over 90% of the cultures of E. coli, Citrobacter, Enterobacter, S. marcescens,Proteus mirabilis, Proteus vulgaris, Proteus rettgeri, P. aeruginosa, S. aureus and enterococci examined were inhibited by less than or equal to 64 micrograms/ml fosfomycin.

Agar↗

Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey.

In order to assess the resistance profile for fosfomycin trometamol after several years of clinical use in Italy, this study has explored the susceptibility to fosfomycin and eight other antibacterial drugs of 6,021 strains isolated from 23,816 urines during 1990 in three teaching hospitals located in Genoa, Parma and Catania. Gram-negative strains, notably Escherichia coli (41.6%), were primarily involved. Amoxicillin was the least active compound with resistance in 41.4% of the isolates. Fosfomycin showed the lowest rate of resistance in both gram-negative (2.8%) and gram-positive (2.1%) pathogens. This was followed by norfloxacin with a resistance rate of 11.8% and netilmicin with 12.2%. These results indicate that fosfomycin-trometamol may continue to be used in single-dose treatment of urinary tract infections even in the absence of microbiological data since the prevalence of resistance to the drug is, at present, so low that therapeutic failure is highly improbable.

Anti-Bacterial Agents↗

The comparative activity of fosfomycin trometamol against organisms isolated from infected urines.

Five hundred urinary pathogens, collected from patients of general practitioners and hospital in-patients, were identified and tested for susceptibility to fosfomycin, ampicillin, cephalexin, nalidixic acid, nitrofurantoin, trimethoprim and sulfamethoxazole. Overall, 83% of the isolates were sensitive to fosfomycin, comprising 89% of the out-patient strains and 77% of the in-patient isolates. This degree of sensitivity was similar to that of cephalexin, nalidixic acid and trimethoprim, but higher than that observed with ampicillin, nitrofurantoin and sulfamethoxazole. Fosfomycin generally showed a broad spectrum of activity, but was less active than some other compounds against Klebsiella spp. and streptococci. More than 70% of strains resistant to ampicillin, sulfamethoxazole or trimethoprim were sensitive to fosfomycin indicating that cross resistance is not presently a problem.

Anti-Bacterial Agents↗

Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: a review.

Bacteriuria in pregnancy occurs in about one in 20 pregnant women and is usually initially asymptomatic. It is an important marker for acute symptomatic infection (often pyelonephritis) later in pregnancy, which occurs in about one in four bacteriurics. Several considerations surround the antibiotic treatment of the asymptomatic infection; these include a low frequency of in vitro resistance to the agent used, lack of toxicity to the foetus, a low incidence of gastrointestinal side effects, good compliance and proven efficacy. Fosfomycin trometamol seems to fit these requirements. In three controlled studies (two multicentric) 250 patients were treated with fosfomycin trometamol in a 3 g (as fosfomycin) single dose; 197 patients were given one of three other agents. Cure rates for fosfomycin trometamol were 77-94% (68-94% for other agents), which was satisfactory in an infection which is sometimes difficult to eradicate. Further studies are needed in this important but accessible group of patients. Opportunities should be taken to study more foetal outcomes and provide more data on gastro-intestinal tolerability.

Bacteriuria↗

Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience.

In the literature there are three comparative and two open studies in which 1,395 patients received 3 g of fosfomycin trometamol per os 12 or three hours before and 24 hours after surgery: 625 patients received control substances or placebo. In the comparative studies the incidence of postoperative bacteriuria in patients treated with fosfomycin trometamol ranged from 2.9 to 7.6% at one week and from 1.2 to 3.2% at two to four weeks follow-up, and was lower than in patients treated with reference drugs or placebo. In the open study, postoperative bacteriuria ranged from 2.9 to 6.0% at one week follow-up. In our open study, 70 patients were evaluable. Four out of 70 (5.7%) developed fever > or = 38 degrees C, with positive urine culture, during the first three postoperative days. At two weeks follow-up another 5.7% showed a symptomatic urinary tract infection with a cumulative infection rate of 11.4%. In all cases, the bacteria were resistant to fosfomycin trometamol. A low incidence, 4.2%, of side effects, mainly related to the gastrointestinal tract, was observed. Fosfomycin trometamol proved to be effective with the advantage of no risk of cross resistance, practical pharmaceutical formulation with good patient compliance, good safety profile with few side effects and a satisfactory cost/benefit ratio.

Aged↗

Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics.

The intracellular bactericidal activity of fosfomycin was compared to that of other anti-staphylococcal agents. Two staphylococcal strains (one isolate of Staphylococcus aureus and one isolate of Staphylococcus epidermidis) were incubated in vitro with human granulocytes isolated from volunteers. After phagocytosis and removal of residual extracellular bacteria, the cells were resuspended in the presence of clinically relevant concentrations of fosfomycin, teicoplanin, vancomycin and rifampin. The number of bacteria surviving intracellularly was determined by colony counts after osmotic lysis of the granulocytes at different time intervals. Incubation with fosfomycin resulted in a mean reduction of intracellular bacteria by approximately two logs of ten within 18 h for both staphylococcal strains. Although less effective than rifampin, fosfomycin showed a significantly higher intracellular activity than the glycopeptide antibiotics in this model.

Anti-Bacterial Agents↗